Stefano Brini

Stefano Brini

Auto-generated profile, based on publicly available information

Stefano Brini

School of Health Sciences, City, University of London, London, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Health Technology Assessment
Verified
Journal Article
Closed access
PDF file
RGRebecca Gathercole
Rebecca Gathercole
RBRosie Bradley
Rosie Bradley
EHEmma Harper
Emma Harper
LDLucy Davies
Lucy Davies
LPLynn Pank
Lynn Pank
RHRobert Howard
Robert Howard
Background: Assistive technology and telecare have been promoted to manage the risks associated with independent living for people with dementia, but there is limited evidence of their effectiveness.Objectives: This trial aimed to establish whether or not assistive technology and telecare assessments and interventions extend the time that people with dementia can continue to live independently at home and whether or not they are cost-effective. Caregiver burden, the quality of life of caregivers and of people with dementia and whether or not assistive technology and telecare reduce safety risks were also investigated.Design: This was a pragmatic, randomised controlled trial. Blinding was not undertaken as it was not feasible to do so. All consenting participants were included in an intention-to-treat analysis.Setting: This trial was set in 12 councils in England with adult social services responsibilities.Participants: Participants were people with dementia living in the community who had an identified need that might benefit from assistive technology and telecare.Interventions: Participants were randomly assigned to receive either assistive technology and telecare recommended by a health or social care professional to meet their assessed needs (a full assistive technology and telecare package) or a pendant alarm, non-monitored smoke and carbon monoxide detectors and a key safe (a basic assistive technology and telecare package).Main outcome measures: The primary outcomes were time to admission to care and cost-effectiveness. Secondary outcomes assessed caregivers using the 10-item Center for Epidemiological Studies Depression Scale, the State–Trait Anxiety Inventory 6-item scale and the Zarit Burden Interview.Results: Of 495 participants, 248 were randomised to receive full assistive technology and telecare and 247 received the limited control. Comparing the assistive technology and telecare group with the control group, the hazard ratio for institutionalisation was 0.76 (95% confidence interval 0.58 to 1.01;p = 0.054). After adjusting for an imbalance in the baseline activities of daily living score between trial arms, the hazard ratio was 0.84 (95% confidence interval 0.63 to 1.12;p = 0.20). At 104 weeks, there were no significant differences between groups in health and social care resource use costs (intervention group – control group difference: mean –£909, 95% confidence interval –£5336 to £3345) or in societal costs (intervention group – control group difference: mean –£3545; 95% confidence interval –£13,914 to £6581). At 104 weeks, based on quality-adjusted life-years derived from the participant-rated EuroQol-5 Dimensions questionnaire, the intervention group had 0.105 (95% confidence interval –0.204 to –0.007) fewer quality-adjusted life-years than the control group. The number of quality-adjusted life-years derived from the proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups. Caregiver outcomes did not differ between groups over 24 weeks.Limitations: Compliance with the assigned trial arm was variable, as was the quality of assistive technology and telecare needs assessments. Attrition from assessments led to data loss additional to that attributable to care home admission and censoring events.Conclusions: A full package of assistive technology and telecare did not increase the length of time that participants with dementia remained in the community, and nor did it decrease caregiver burden, depression or anxiety, relative to a basic package of assistive technology and telecare. Use of the full assistive technology and telecare package did not increase participants’ health and social care or societal costs. Quality-adjusted life-years based on participants’ EuroQol-5 Dimensions questionnaire responses were reduced in the intervention group compared with the control group; groups did not differ in the number of quality-adjusted life-years based on the proxy-rated EuroQol-5 Dimensions questionnaire.Future work: Future work could examine whether or not improved assessment that is more personalised to an individual is beneficial.Trial registration: Current Controlled Trials ISRCTN86537017.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 25, No. 19. See the NIHR Journals Library website for further project information.

8 February 2020 in Neuropsychology Review
Verified
Journal Article
Open access
PDF file
SBStefano Brini
Stefano Brini
HSHamid R. Sohrabi
Hamid R. Sohrabi
JHJeffrey J. Hebert
Jeffrey J. Hebert
MFMitchell R. L. Forrest
Mitchell R. L. Forrest
MLMatti Laine
Matti Laine
TFTimothy J. Fairchild
Timothy J. Fairchild
Some studies have linked bilingualism with a later onset of dementia, Alzheimer’s disease (AD), and mild cognitive impairment (MCI). Not all studies have observed such relationships, however. Differences in study outcomes may be due to methodological limitations and the presence of confounding factors within studies such as immigration status and level of education. We conducted the first systematic review with meta-analysis combining cross-sectional studies to explore if bilingualism might delay symptom onset and diagnosis of dementia, AD, and MCI. Primary outcomes included the age of symptom onset, the age at diagnosis of MCI or dementia, and the risk of developing MCI or dementia. A secondary outcome included the degree of disease severity at dementia diagnosis. There was no difference in the age of MCI diagnosis between monolinguals and bilinguals [mean difference: 3.2; 95% confidence intervals (CI): −3.4, 9.7]. Bilinguals vs. monolinguals reported experiencing AD symptoms 4.7 years (95% CI: 3.3, 6.1) later. Bilinguals vs. monolinguals were diagnosed with dementia 3.3 years (95% CI: 1.7, 4.9) later. Here, 95% prediction intervals showed a large dispersion of effect sizes (−1.9 to 8.5). We investigated this dispersion with a subgroup meta-analysis comparing studies that had recruited participants with dementia to studies that had recruited participants with AD on the age of dementia and AD diagnosis between mono- and bilinguals. Results showed that bilinguals vs. monolinguals were 1.9 years (95% CI: −0.9, 4.7) and 4.2 (95% CI: 2.0, 6.4) older than monolinguals at the time of dementia and AD diagnosis, respectively. The mean difference between the two subgroups was not significant. There was no significant risk reduction (odds ratio: 0.89; 95% CI: 0.68–1.16) in developing dementia among bilinguals vs. monolinguals. Also, there was no significant difference (Hedges’g = 0.05; 95% CI: −0.13, 0.24) in disease severity at dementia diagnosis between bilinguals and monolinguals, despite bilinguals being significantly older. The majority of studies had adjusted for level of education suggesting that education might not have played a role in the observed delay in dementia among bilinguals vs. monolinguals. Although findings indicated that bilingualism was on average related to a delayed onset of dementia, the magnitude of this relationship varied across different settings. This variation may be due to unexplained heterogeneity and different sources of bias in the included studies. Registration: PROSPERO CRD42015019100.

8 December 2022 in Clinical Psychology Review
Verified
Journal Article
Open access
SBS. Brini
S. Brini
NBN.I. Brudasca
N.I. Brudasca
AHA. Hodkinson
A. Hodkinson
KKK. Kaluzinska
K. Kaluzinska
AWA. Wach
A. Wach
MBM.M. Bala
M.M. Bala
We re-analysed data from published meta-analyses testing the effects of Transcranial Magnetic Stimulation (TMS) on Major Depressive Disorder (MDD) in adults. We applied up-to-date meta-analytic techniques for handling heterogeneity including the random-effects Hartung-Knapp-Sidik-Jonkman method and estimated 95% prediction intervals. Heterogeneity practices in published meta-analyses were assessed as a secondary aim. We performed systematic searches of systematic reviews with meta-analyses that included randomised controlled trials assessing the efficacy, tolerability, and side effects of TMS on MDD. We performed risk of bias assessment using A MeaSurement Tool to Assess Reviews (AMSTAR) 2 and re-analysed meta-analyses involving 10 or more primary studies. We included 29 systematic reviews and re-analysed 15 meta-analyses. Authors of all meta-analyses interpreted findings to suggest TMS is safe and effective for MDD. Our re-analysis showed that in 14 out of 15 meta-analyses, the 95% prediction intervals included the null and captured values in the opposite effect direction. We also detected presence of small-study effects in some meta-analyses and 24 out of 25 systematic reviews received an AMSTAR 2 rating classed as critically low. Authors of all included meta-analyses interpreted findings to suggest TMS is safe and effective for MDD despite lack of comprehensive investigation of heterogeneity. Our re-analysis revealed the direction and magnitude of treatment effects vary widely across different settings. We also found high risk of bias in the majority of included systematic reviews and presence of small-study effects in some meta-analyses. Because of these reasons, we argue TMS for MDD may not be as effective and potentially less tolerated in some populations than current evidence suggests.

23 September 2017 in Sports Medicine
Verified
Journal Article
Closed access
PDF file
SBStefano Brini
Stefano Brini
HSHamid R. Sohrabi
Hamid R. Sohrabi
JPJeremiah J. Peiffer
Jeremiah J. Peiffer
MKMira Karrasch
Mira Karrasch
HHHeikki Hämäläinen
Heikki Hämäläinen
TFTimothy Fairchild
Timothy Fairchild

29 January 2022 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
MKMariam Kirvalidze
Mariam Kirvalidze
AHAlexander Hodkinson
Alexander Hodkinson
DSDawid Storman
Dawid Storman
TFTimothy J. Fairchild
Timothy J. Fairchild
MBMalgorzata M. Bała
Malgorzata M. Bała
SBStefano Brini
Stefano Brini

18 April 2020 in British Journal of Health Psychology
Verified
Journal Article
Closed access
PDF file
KGKonstadina Griva
Konstadina Griva
RYRussell K. L. Yoong
Russell K. L. Yoong
MNMooppil Nandakumar
Mooppil Nandakumar
MRMoothathamby Rajeswari
Moothathamby Rajeswari
EKEric Y. H. Khoo
Eric Y. H. Khoo
SNStanton P. Newman
Stanton P. Newman